18 results found.

Heterozygous Familial Hypercholesterolemia Clinical Trial using PF-04950615; Placebo

Pfizer - Recruiting 18 years or older.
- A 52 Week, Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia.
PF-04950615; Placebo

Hypercholesterolemia Clinical Trial using Evolocumab (AMG 145); Placebo

Amgen - Recruiting 18 years or older.
- A Randomized, Double-Blind, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization..
Evolocumab (AMG 145); Placebo

Severe Familial Hypercholesterolemia Clinical Trial using Evolocumab (AMG145)

Amgen - Recruiting 12 years to 80 years.
- A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia.
Evolocumab (AMG145)

Hypercholesterolemia, or Heterozygous Familial Clinical Trial using mipomersen sodium 200 mg; Placebo; mipomersen sodium 70 mg

Sanofi - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol.
mipomersen sodium 200 mg; Placebo; mipomersen sodium 70 mg

Hypercholesterolemia Clinical Trial using ETC-1002; Placebo

Esperion Therapeutics - Recruiting 18 years to 80 years.
- A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of ETC-1002 Versus Placebo in Patients With Hypercholesterolemia Receiving Ongoing Statin Therapy.
ETC-1002; Placebo

Atherosclerosis, or Hypercholesterolemia Clinical Trial using LDL. Cholesterol (Statin Drugs); HMG-CoA Reductase Inhibitors

National Institutes of Health Clinical Center (CC) - Recruiting 55 years or older.
- Randomized Trial of Imaging Versus Risk Factor Based Therapy for Plaque Regression.
LDL. Cholesterol (Statin Drugs); HMG-CoA Reductase Inhibitors

Hypercholesterolemia Clinical Trial using Alirocumab SAR236553 (REGN727)

Sanofi - Recruiting 18 years or older.
- Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia.
Alirocumab SAR236553 (REGN727)

Hypercholesterolemia Clinical Trial using alirocumab SAR236553 (REGN727) Dose Regimen A; alirocumab SAR236553 (REGN727) Dose Regimen B; alirocumab matching placebo

Sanofi - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients With Primary Hypercholesterolemia Not Treated With a Statin.
alirocumab SAR236553 (REGN727) Dose Regimen A; alirocumab SAR236553 (REGN727) Dose Regimen B; alirocumab matching placebo

Hyperlipidemia, Hypercholesterolemia, or Dyslipidemia Clinical Trial

Ohio State University - Recruiting 18 years or older.
- An Observational Study Investigating Genetic Influences on Statin Plasma Concentrations in Adults Taking Atorvastatin, Simvastatin, or Lovastatin.

Hypercholesterolemia Clinical Trial using Anacetrapib 100 mg; Placebo for anacetrapib 100 mg; Anacetrapib 25 mg; Placebo for anacetrapib 25 mg

Merck Sharp & Dohme Corp. - Recruiting 18 years to 80 years.
- A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C.
Anacetrapib 100 mg; Placebo for anacetrapib 100 mg; Anacetrapib 25 mg; Placebo for anacetrapib 25 mg

Hypercholesterolemia Clinical Trial using Atorvastatin calcium 10 mg

Pfizer - Recruiting 18 years or older.
- A Multicenter, Actual Use Trial In A Simulated Over-the-Counter Environment Of Atorvastatin Calcium 10 mg.
Atorvastatin calcium 10 mg

Hypercholesterolemia Clinical Trial using Anacetrapib; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 80 years.
- A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C.
Anacetrapib; Placebo

Obesity, or Hypercholesterolemia Clinical Trial using Cooked Lentils; Potato-Based Foods

University of Manitoba - Recruiting 30 years to 75 years.
- Lentils as a Functional Food to Improve Glucose Tolerance and Decrease Cardiovascular Disease Risk in Hypercholesterolemic Overweight Individuals.
Cooked Lentils; Potato-Based Foods

Hypercholesterolemia, or Coronary Artery Disease Clinical Trial using Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]; Lipitor (Atorvastatin) monotherapy

Kumamoto University - Recruiting 30 years to 85 years.
- Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound.
Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]; Lipitor (Atorvastatin) monotherapy

Hypercholesterolemia Clinical Trial using Statin

University of Kansas - Recruiting 18 years to 70 years.
- A Study Comparing the Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on Plasma Levels of CoQ10 (SPARQ).
Statin

Type 2 Diabetes Mellitus, or Hypercholesterolemia Clinical Trial using Atorvastatin; Placebo

University of Roma La Sapienza - Recruiting 18 years to 75 years.
- Effects on Oxidative Stress, Coagulation, Platelet Activation and Inflammatory Indexes of Atorvastatin and/or Aspirin Treatment in Patients at High Risk of Vascular Events.
Atorvastatin; Placebo

Hypercholesterolemia Clinical Trial using Psyllium husks; Isolated soy protein; Isolated whey protein; Microcrystalline cellulose

Aalborg Universityhospital - Recruiting 18 years to 75 years.
- Additive Cholesterol Lowering Effect by Concomitant Treatment With Psyllium Husks and Isolated Soy Protein in Addition to Heart-healthy Diet in Hypercholesterolemia.
Psyllium husks; Isolated soy protein; Isolated whey protein; Microcrystalline cellulose

Hypercholesterolemia, or Medication Adherence Clinical Trial using Medication adherence intervention; Attention-control

University of Missouri-Columbia - Recruiting 60 years or older.
- Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults.
Medication adherence intervention; Attention-control